Blockchain Registration Transaction Record
Clene (NASDAQ: CLNN) Developing Breakthrough Treatment for Neurodegenerative Diseases
Clene (NASDAQ: CLNN) is making significant strides in developing a breakthrough treatment for neurodegenerative diseases with its innovative candidate, CNM-Au8. Targeting the NAD+ pathway, this treatment offers new hope for patients with ALS, MS, and Parkinson’s disease.
This news matters because Clene's innovative treatment, CNM-Au8, offers new hope for patients with ALS, MS, and Parkinson's disease. The company's focus on improving mitochondrial health and targeting the NAD+ pathway has the potential to transform the treatment of neurodegenerative diseases, impacting millions of people worldwide.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0x25a0739446559e53dadda994c9b06a87e92b25bc85c6ced700cee6d17763c24b |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | mask0gfg-cdc15fe1dd1f20e1440e62d3bb721eec |